There are currently 1549 clinical trials in Dallas, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Southwestern Medical Center, UT Southwestern Medical Center, UT Southwestern/Simmons Cancer Center-Dallas and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
Recruiting
This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called a "study drug" or called "study drugs" when combined) compared with an approved medication called pembrolizumab. The objective of this study is to see if the combination of fianlimab and cemiplimab is an effective treatment compared to pembrolizumab in patients that have had melanoma removal surgery but are still at hi... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
05/21/2024
Locations: The University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Melanoma
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Recruiting
This is a two-part study of pembrolizumab (MK-3475) in pediatric participants who have any of the following types of cancer: advanced melanoma (6 months to <18 years of age), advanced, relapsed or refractory programmed death-ligand 1 (PD-L1)-positive malignant solid tumor or other lymphoma (6 months to <18 years of age), relapsed or refractory classical Hodgkin lymphoma (rrcHL) (3 years to <18 years of age), or advanced relapsed or refractory microsatellite-instability-high (MSI-H) solid tumors... Read More
Gender:
All
Ages:
Between 6 months and 17 years
Trial Updated:
05/21/2024
Locations: Call for Information (Investigational Site 0054), Dallas, Texas
Conditions: Melanoma, Lymphoma, Solid Tumor, Classical Hodgkin Lymphoma, Microsatellite-instability-high Solid Tumor
Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial
Recruiting
COVID-19 can trigger a dysregulated immune response, and previous studies have shown that immune modulation can improve outcomes in hospitalized patients. This trial is designed to determine whether intensification of immune modulation early in the course of the disease (while patients are on low flow oxygen) with abatacept (active arm) combined with standard of care (SOC) improves recovery as compared with placebo + SOC (placebo arm). For both groups, intensification of immunomodulation will be... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/21/2024
Locations: Parkland Health and Hospital Systems (084-002), Dallas, Texas +2 locations
Conditions: COVID-19
remedē System Therapy Study
Recruiting
The purpose of this non-randomized post market study is to collect clinical data on the safety and effectiveness of the remedē System in a real-world setting.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/21/2024
Locations: Baylor Scott and White - Dallas, Dallas, Texas
Conditions: Central Sleep Apnea
Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis
Recruiting
Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis
Gender:
All
Ages:
Between 10 years and 17 years
Trial Updated:
05/21/2024
Locations: University of Texas Southwestern Main Center, Dallas, Texas
Conditions: Multiple Sclerosis (MS)
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)
Recruiting
The purpose of this study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepressant (selective serotonin reuptake inhibitor [SSRI] or serotonin and norepinephrine reuptake inhibitor [SNRI]) in all participants with major depressive disorder (MDD).
Gender:
All
Ages:
Between 18 years and 74 years
Trial Updated:
05/21/2024
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Depressive Disorder, Major
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
Recruiting
The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the clinical consequences of AKI (MAKE) at 90 days in adult participants with CKD who undergo non-emergent cardiac surgery with CPB.
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
05/21/2024
Locations: Research Site, Dallas, Texas
Conditions: Chronic Kidney Disease, CKD, Cardiac Disease, Cardiopulmonary Bypass
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Recruiting
The purpose of this study is to assess the efficacy and safety of opevesostat plus hormone replacement therapy (HRT) compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) previously treated with one next-generation hormonal agent (NHA). The primary study hypotheses are that opevesostat is superior to alternative abiraterone acetate or enzalutamide with respect to radiographic progression free survival (rPFS) per P... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/21/2024
Locations: Urology Clinics of North Texas, PLLC ( Site 0077), Dallas, Texas
Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)
Recruiting
GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/21/2024
Locations: Texas Oncology-Dallas Presbyterian Hospital (USOR), Dallas, Texas
Conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis
Recruiting
The purpose of this study is to evaluate the efficacy of guselkumab compared to an inactive drug in participants with low body surface area moderate plaque psoriasis and special site involvement.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/21/2024
Locations: Modern Research Associates PLLC, Dallas, Texas +2 locations
Conditions: Moderate Plaque Psoriasis
A Study of Valemetostat in Combination With DXd ADCs in Subjects With Solid Tumors
Recruiting
This study will evaluate the safety, tolerability, and efficacy of valemetostat tosylate in combination with DXd ADC in patients with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/21/2024
Locations: Mary Crowley Cancer Research Centers, Dallas, Texas
Conditions: Advanced Solid Tumor
Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
Recruiting
A randomized, double-blind, placebo controlled, 2-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjogren's syndrome (NEPTUNUS-1)
Gender:
All
Ages:
18 years and above
Trial Updated:
05/21/2024
Locations: Novartis Investigative Site, Dallas, Texas +1 locations
Conditions: Sjogren Syndrome